Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Danyi Wen"'
Publikováno v:
Cells, Vol 11, Iss 23, p 3868 (2022)
As one of the leading causes of death from disease, cancer continues to pose a serious threat to human health globally. Despite the development of novel therapeutic regimens and drugs, the long-term survival of cancer patients is still very low, espe
Externí odkaz:
https://doaj.org/article/e99f4ed845df406d89450ad029fcfb69
Autor:
Xiaoxi Dong, Tiantian Zheng, Minhua Zhang, Chao Dai, Lili Wang, Lei Wang, Ruipeng Zhang, Yuan Long, Danyi Wen, Feng Xie, Yue Zhang, Yong Huang, Jianguo Dong, Huan Liu, Pan Du, Bonnie L. King, Winston Tan, Shidong Jia, Chris X. Lu, Manish Kohli, Haitao Wang, Jianjun Yu
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Current liquid biopsy assays lack sufficient sensitivity to detect copy number loss, which limits the interrogation of critical tumor suppressor gene deletions during cancer progression and treatment. Here we describe a liquid biopsy assay with impro
Externí odkaz:
https://doaj.org/article/8d43e9fdf19046549c4e88294af7337c
Autor:
Feifei Zhang, Wenjie Wang, Yuan Long, Hui Liu, Jijun Cheng, Lin Guo, Rongyu Li, Chao Meng, Shan Yu, Qingchuan Zhao, Shun Lu, Lili Wang, Haitao Wang, Danyi Wen
Publikováno v:
Cancer Communications, Vol 38, Iss 1, Pp 1-12 (2018)
Abstract Background Patient-derived organoids and xenografts (PDXs) have emerged as powerful models in functional diagnostics with high predictive power for anticancer drug response. However, limitations such as engraftment failure and time-consuming
Externí odkaz:
https://doaj.org/article/e762398f8d37400ea5384e85b476c5bb
Publikováno v:
Cancer Communications, Vol 38, Iss 1, Pp 1-7 (2018)
Abstract Background Treatment guidelines for a variety of cancers have been increasingly used in clinical practice, and have resulted in major improvement in patient outcomes. However, recommended regimens (even first-line treatments) are clearly not
Externí odkaz:
https://doaj.org/article/46239af3ac62482da3b9b27d101256f7
Publikováno v:
Cancer Communications, Vol 38, Iss 1, Pp 1-12 (2018)
Abstract Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusions show dramatic responses to specific tyrosine kinase inhibitors (TKIs); however, after 1
Externí odkaz:
https://doaj.org/article/605a10088897424a991676a6833aa94e
Autor:
Hong Xin, Ke Wang, Gang Hu, Fubo Xie, Kedong Ouyang, Xuzhen Tang, Minjun Wang, Danyi Wen, Yizhun Zhu, Xiaoran Qin
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e85308 (2014)
Hepatocellular carcinoma (HCC) is a common cancer with poor prognosis worldwide and the molecular mechanism is not well understood. This study aimed to establish a collection of human HCC cell lines from patient-derived xenograft (PDX) models. From t
Externí odkaz:
https://doaj.org/article/1492cc0f37f1486984079837d2f53e2c
Publikováno v:
Cancer Research. 83:5200-5200
Currently more and more immunotherapeutic drugs and engineered cells have been developed to use human immune system against cancer. While humanized peripheral blood mononuclear cell reconstitution in immune deficient mice is a forward-straight model
Publikováno v:
Cancer Research. 83:43-43
MiniPDX® represents a novel in vivo drug sensitivity test with fast turnaround (7-10 days), using either fresh patient tumor samples or tissues from established PDX models. We systematically evaluated and compared the response rates of MiniPDX® ass
Background: This study aimed to establish patient-derived xenografts (PDX) models of multiple myeloma and to evaluate the feasibility of using the PDX model to test chemotherapy responsiveness. Methods: Three patients with multiple myeloma were enrol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77bc74ce6ae8ebbf75286f8714c4f91c
https://doi.org/10.21203/rs.3.rs-1574488/v1
https://doi.org/10.21203/rs.3.rs-1574488/v1
Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are malignant clonal diseases of the hematopoietic system with an unsatisfactory overall prognosis. The main obstacle is the increased resistance of AML and ALL cells to chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::886c328016dc6f946f375177e99fd1d0
https://doi.org/10.21203/rs.3.rs-1444342/v1
https://doi.org/10.21203/rs.3.rs-1444342/v1